PL3255061T3 - Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia - Google Patents

Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia

Info

Publication number
PL3255061T3
PL3255061T3 PL17168021T PL17168021T PL3255061T3 PL 3255061 T3 PL3255061 T3 PL 3255061T3 PL 17168021 T PL17168021 T PL 17168021T PL 17168021 T PL17168021 T PL 17168021T PL 3255061 T3 PL3255061 T3 PL 3255061T3
Authority
PL
Poland
Prior art keywords
deplection
implementation
stem cell
endogenous stem
selective immunological
Prior art date
Application number
PL17168021T
Other languages
English (en)
Inventor
Irving L. Weissman
Agnieszka Czechowicz
Deepta Bhattacharya
Daniel Kraft
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39468595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3255061(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL3255061T3 publication Critical patent/PL3255061T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL17168021T 2006-11-03 2007-11-02 Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia PL3255061T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85643506P 2006-11-03 2006-11-03
PCT/US2007/083529 WO2008067115A2 (en) 2006-11-03 2007-11-02 Selective immunodepletion of endogenous stem cell niche for engraftment
EP17168021.8A EP3255061B1 (en) 2006-11-03 2007-11-02 Selective immunodepletion of endogenous stem cell niche for engraftment
EP07871350.0A EP2088864B2 (en) 2006-11-03 2007-11-02 Selective immunodepletion of endogenous stem cell niche for engraftment

Publications (1)

Publication Number Publication Date
PL3255061T3 true PL3255061T3 (pl) 2021-12-06

Family

ID=39468595

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17168021T PL3255061T3 (pl) 2006-11-03 2007-11-02 Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia

Country Status (9)

Country Link
US (5) US20100226927A1 (pl)
EP (3) EP3255061B1 (pl)
DK (1) DK2088864T3 (pl)
ES (2) ES2882360T3 (pl)
HU (1) HUE034583T2 (pl)
PL (1) PL3255061T3 (pl)
PT (1) PT3255061T (pl)
SI (1) SI3255061T1 (pl)
WO (1) WO2008067115A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3255061T3 (pl) 2006-11-03 2021-12-06 The Board Of Trustees Of The Leland Stanford Junior University Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
WO2012135253A1 (en) * 2011-03-29 2012-10-04 Geron Corporation Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
SG11201508027PA (en) * 2013-02-28 2015-11-27 Harvard College Methods and compositions for mobilizing stem cells
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
HRP20210057T4 (hr) 2014-08-26 2025-07-18 The Board Of Trustees Of The Leland Stanford Junior University Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije
WO2016154588A1 (en) * 2015-03-25 2016-09-29 Children's Hospital Medical Center Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
AU2016246707B2 (en) 2015-04-06 2021-03-25 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
EA039364B1 (ru) * 2015-10-09 2022-01-18 Президент Энд Феллоус Оф Гарвард Колледж Композиции и способы для немиелоаблативного кондиционирования
US9957576B2 (en) 2016-04-21 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
KR20190038537A (ko) * 2016-06-17 2019-04-08 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
EP3471772A4 (en) * 2016-06-17 2020-03-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
WO2018071871A1 (en) * 2016-10-13 2018-04-19 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
JP7305539B2 (ja) * 2016-11-02 2023-07-10 ウニベルシテート バーゼル 細胞療法に使用するための、免疫学的に識別できる細胞表面変異体
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
EP3570850A4 (en) * 2017-01-18 2020-10-14 Thalia Papayannopoulou PACKAGING COMPOSITIONS AND METHODS FOR A TRANSPLANT RECEIVER
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
JP7321934B2 (ja) * 2017-01-30 2023-08-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 幹細胞移植のための非遺伝毒性移植前処置レジメン
CN117959418A (zh) * 2017-03-13 2024-05-03 波赛达治疗公司 用于选择性消除和替换造血干细胞的组合物和方法
WO2018183613A1 (en) 2017-03-31 2018-10-04 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
CN111372608B (zh) 2017-10-24 2024-07-02 克里斯珀医疗股份公司 用于耗尽cd117+细胞的组合物和方法
IL316155A (en) 2017-11-29 2024-12-01 Heidelberg Pharma Res Compositions and Methods for the Depletion of CD5(PLUS) CELLS
US11642379B2 (en) 2017-12-08 2023-05-09 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment
JP7642531B2 (ja) 2018-05-11 2025-03-10 ビーム セラピューティクス インク． プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法
UY38265A (es) 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
EP3817773B1 (en) 2018-11-26 2024-07-24 Forty Seven, Inc. Humanized antibodies against c-kit
JP2022510634A (ja) 2018-11-28 2022-01-27 フォーティ セブン， インコーポレイテッド 除去レジメンに抵抗性の遺伝的に改変されたｈｓｐｃ
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
CN118076642A (zh) * 2021-10-04 2024-05-24 美国政府卫生与公众服务部 抗cmpl二价scfv及其用途
WO2023183555A1 (en) * 2022-03-25 2023-09-28 Memorial Sloan-Kettering Cancer Center Method of promoting thymic recovery by administering hematopoietic stem cells with low c-kit expression
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2107553C (en) 1991-04-05 2001-07-31 Nancy Lin Monoclonal antibodies to stem cell factor receptors
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
DE69723531T3 (de) 1996-10-01 2012-09-06 Geron Corp. Katalytische Untereinheit der menschlichen Telomerase
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
ATE510855T1 (de) * 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
AU2002338807A1 (en) 2001-09-27 2003-04-14 Novartis Ag Use of c-kit inhibitors for the treatment of myeloma
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
PL3255061T3 (pl) 2006-11-03 2021-12-06 The Board Of Trustees Of The Leland Stanford Junior University Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia

Also Published As

Publication number Publication date
EP3255061B1 (en) 2021-06-16
EP2088864B2 (en) 2025-08-27
US20230128340A1 (en) 2023-04-27
WO2008067115A3 (en) 2008-11-06
EP3960764A1 (en) 2022-03-02
US20100226927A1 (en) 2010-09-09
US20240400709A1 (en) 2024-12-05
ES2642205T3 (es) 2017-11-15
ES2642205T5 (en) 2025-11-03
US20180327507A1 (en) 2018-11-15
WO2008067115A2 (en) 2008-06-05
SI3255061T1 (sl) 2021-09-30
HUE034583T2 (en) 2018-02-28
EP2088864A4 (en) 2010-09-29
EP3255061A1 (en) 2017-12-13
US20170066834A1 (en) 2017-03-09
US10072091B2 (en) 2018-09-11
PT3255061T (pt) 2021-07-26
EP2088864A2 (en) 2009-08-19
EP2088864B1 (en) 2017-08-16
DK2088864T3 (en) 2017-10-02
US11905333B2 (en) 2024-02-20
ES2882360T3 (es) 2021-12-01

Similar Documents

Publication Publication Date Title
PL3255061T3 (pl) Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia
EP2094839A4 (en) EXPANSION OF HEMATOPOIETIC STEM CELLS
PL2343362T3 (pl) Udoskonalony sposób hodowania komórek
EP2007874A4 (en) PROPAGATION OF PRIMARY CELLS
HUE042044T2 (hu) Elektroporációs készülékek sejtek elektroporációjára emlõsökben
DK2135081T3 (da) Fremgangsmåder i forbindelse med celleoverfladeglycosylering
SE0950586L (sv) Förbättrad odling av stamceller
DK2471905T3 (da) Placentastamcellepopulationer
EP2148569A4 (en) METHOD AND COMPOSITIONS FOR THE SELF-RENEWAL OF STEM CELLS
IS8637A (is) Blóðflögur úr stofnfrumum
EP2003722A4 (en) STACK CELL
DK2419429T3 (da) Imidazopyraziner som inhibitorer af proteinkinaser
DE602007000497D1 (de) Expansionsventil
EP1979951A4 (en) SOLAR CELL
SMP201100024B (it) Composti che espandono cellule staminali ematopoietiche
DE602007010524D1 (de) Sekundärbatterie
ATE465169T1 (de) Hemmstoffe des progesteron-rezeptors
DE602007007005D1 (de) Kompressor für Brennstoffzelle
EP2095430A4 (en) SOLAR CELL
EP2099090A4 (en) SOLAR CELL SENSITIZED TO COLOR
DE112007001371B8 (de) Brennstoffzelle
DE112007002407B8 (de) Brennstoffzelle
EP2045866A4 (en) Secondary battery
DK2027150T3 (da) Allo-begrænsede peptid-specifikke t-celler
BRPI1014635A2 (pt) compostos heterocíclicos e de expansão para células-tronco hematopoiéticas